文献速递心力衰竭与心肌病

达格列净对心衰患者症状与6分钟步行距离的影响:DETERMINE随机临床试验

Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials.
PubMed 文献 · Circulation · 2023-12-07

DETERMINE双盲安慰剂对照多中心试验评估达格列净对射血分数降低(313例)和保留(504例)心衰患者KCCQ症状总分、躯体限制评分及6分钟步行距离的影响。结果显示达格列净改善射血分数降低患者的KCCQ症状总分,但未改善躯体限制评分或6分钟步行距离;射血分数保留患者上述结局均未改善。事后汇总分析显示达格列净改善KCCQ症状总分和躯体限制评分,但未改善6分钟步行距离。

要点

  • 达格列净改善射血分数降低心衰患者的KCCQ症状总分
  • 达格列净未改善射血分数降低患者的躯体限制评分或6分钟步行距离
  • 射血分数保留心衰患者上述结局均未显著改善

核心结论

  • 达格列净改善射血分数降低心衰患者的KCCQ症状总分,但未改善躯体限制评分或6分钟步行距离。
  • 达格列净未改善射血分数保留心衰患者的KCCQ症状总分、躯体限制评分或6分钟步行距离。
  • 事后汇总分析显示达格列净改善KCCQ症状总分和躯体限制评分,但未改善6分钟步行距离。

研究设计与样本

  • DETERMINE为双盲、安慰剂对照、多中心试验,纳入射血分数降低心衰患者313例和射血分数保留心衰患者504例,NYHA心功能II或III级且利钠肽水平升高。
  • 主要结局为治疗16周后KCCQ症状总分、KCCQ躯体限制评分和6分钟步行距离的变化。

主要发现

  • 射血分数降低患者中,达格列净组16周KCCQ症状总分较基线安慰剂校正中位差异为4.2(95%CI 1.0~8.2;P=0.022),支持达格列净。
  • 射血分数降低患者中,KCCQ躯体限制评分安慰剂校正中位差异为4.2(95%CI 0.0~8.3;P=0.058),6分钟步行距离差异为3.2米(95%CI -6.5~13.0;P=0.69)。
  • 射血分数保留患者中,KCCQ症状总分和躯体限制评分16周安慰剂校正中位差异分别为3.2(95%CI 0.4~6.0;P=0.079)和3.1(95%CI -0.1~5.4;P=0.23),6分钟步行距离差异为1.6米(95%CI -5.9~9.0;P=0.67)。
  • 事后汇总分析中,16周安慰剂校正中位差异:KCCQ症状总分3.7(95%CI 1.5~5.9;P=0.005),KCCQ躯体限制评分4.0(95%CI 0.3~4.9;P=0.036),6分钟步行距离2.5米(95%CI -3.5~8.4;P=0.50)。

临床怎么用

  • 达格列净可考虑用于改善射血分数降低心衰患者的症状(KCCQ症状总分),但不应期望其改善6分钟步行距离。
  • 射血分数保留心衰患者中,达格列净对症状和功能能力的获益不显著。

局限性

  • 事后汇总分析为探索性分析,需谨慎解读。
  • 6分钟步行距离作为功能能力指标未显示显著改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sodium-glucose cotransporter 2 inhibitors reduce the risk of worsening heart failure (HF) and cardiovascular death in patients with HF irrespective of left ventricular ejection fraction. It is important to determine whether therapies for HF improve symptoms and functional capacity. METHODS: The DETERMINE (Dapagliflozin Effect on Exercise Capacity Using a 6-Minute Walk Test in Patients With Heart Failure) double-blind, placebo-controlled, multicenter trials assessed the efficacy of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on the Total Symptom Score (TSS) and Physical Limitation Scale (PLS) of the Kansas City Cardiomyopathy Questionnaire (KCCQ) and 6-minute walk distance (6MWD) in 313 patients with HF with reduced ejection fraction (DETERMINE-Reduced) and in 504 patients with HF with preserved ejection fraction (DETERMINE-Preserved) with New York Heart Association class II or III symptoms and elevated natriuretic peptide levels. The primary outcomes were changes in the KCCQ-TSS, KCCQ-PLS, and 6MWD after 16 weeks of treatment. RESULTS: Among the 313 randomized patients with HF with reduced ejection fraction, the median placebo-corrected difference in KCCQ-TSS from baseline at 16 weeks was 4.2 (95% CI, 1.0, 8.2; P=0.022) in favor of dapagliflozin. The median placebo-corrected difference in KCCQ-PLS was 4.2 (95% CI, 0.0, 8.3; P=0.058). The median placebo-corrected difference in 6MWD from baseline at 16 weeks was 3.2 meters (95% CI, -6.5, 13.0; P=0.69). In the 504 patients with HF with preserved ejection fraction, the median placebo-corrected 16-week difference in KCCQ-TSS and KCCQ-PLS was 3.2 (95% CI, 0.4, 6.0; P=0.079) and 3.1 (-0.1, 5.4; P=0.23), respectively. The median 16-week difference in 6MWD was 1.6 meters (95% CI, -5.9, 9.0; P=0.67). In an exploratory post hoc analysis of both trials combined (DETERMINE-Pooled), the median placebo-corrected difference from baseline at 16 weeks was 3.7 (1.5, 5.9; P=0.005) for KCCQ-TSS, 4.0 (0.3, 4.9; P=0.036) for KCCQ-PLS, and 2.5 meters (-3.5, 8.4; P=0.50) for 6MWD. CONCLUSIONS: Dapagliflozin improved the KCCQ-TSS in patients with HF with reduced ejection fraction but did not improve KCCQ-PLS or 6MWD. Dapagliflozin did not improve these outcomes in patients with HF with preserved ejection fraction. In a post hoc analysis including all patients across the full spectrum of ejection fraction, there was a beneficial effect of dapagliflozin on KCCQ-TSS and KCCQ-PLS but not 6MWD. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifiers: NCT03877237 and NCT03877224.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. McMurray, Docherty, de Boer, et al. Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials. Circulation. 2023. PMID: 38059368. doi:10.1161/CIRCULATIONAHA.123.065061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。